Risperidone: Clinical Trials

147 trials of Risperidone, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

102 completed, 18 terminated, 15 unknown, 5 recruiting. 147 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 4147Completed 102, Terminated 18, Unknown 15, Recruiting 5, Withdrawn 4, Not yet recruiting 2, Active not recruiting 1

Follow Risperidone: new trials by email Literature Review of Risperidone trials Research Report on Risperidone

Trials (filtered) newest first · largest first

All 147 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Risperidone vs Cariprazine in Acute Mania
Risperidone, Cariprazine - Bipolar 1 Disorder
Phase 4Not yet recruitingPakistan Institute of Medical Sciences502027-06-012026-06-24
Cerebellum-based Imaging Neural Markers for Antipsychotic Response
risperidone, aripiprazole - Psychosis; Acute
Phase 4RecruitingNorthwell Health1202025-11-012026-05-26
Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.
Group A: (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol,anxiolytics: clonazepam, stedon, tavor antidepressants: seropram),, Group B (Pharmacotherapy and TAU) (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, antidepressants,, Group C (Pharmacotherapy and Psychotherapy) Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, lithium, depakine - Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder
Phase 4Active not recruitingDr. Stavroula Rakitzi842025-06-042026-05-01
Biomarkers to Enhance Early Schizophrenia Treatment
aripiprazole, risperidone, clozapine - Schizophenia Disorder
Phase 4RecruitingNorthwell Health1802024-09-042026-07-31
Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia
Aripiprazole, Risperidone - Schizophrenia
Phase 4CompletedAll India Institute of Medical Sciences, Bhubaneswar602024-04-052025-11-25
Efficacy of Hydroxyzine for Patients With Panic Disorder
Hydroxyzine, Escitalopram Oxalate - Panic Disorder
Phase 4Not yet recruitingSultan Qaboos University802023-12-302023-02-21
An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine
Clozapine, Antipsychotics,Other (non-Clozapine) - Treatment-resistant Schizophrenia
Phase 4TerminatedOhio State University52023-08-162026-02-25
Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine
Lumateperone, Risperidone - Psychosis
Phase 4WithdrawnUniversity of New Mexico2023-05-112025-03-05
"Extended" (Alternate Day) Antipsychotic Dosing
Risperidone, Olanzapine, paliperidone - Schizophrenia and Related Disorders, Drug Administration Schedule
Phase 4RecruitingCentre for Addiction and Mental Health1202022-06-062026-04-13
CLOZAPINE Response in Biotype-1
clozapine, risperidone - Schizophrenia, Schizoaffective Disorder
Phase 4RecruitingUniversity of Texas Southwestern Medical Center5242022-03-012026-05-11
A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
Risperidone 3 mg, Paliperidone Palmitate 50 mg eq., Paliperidone Palmitate 75 mg eq. - Schizophrenia
Phase 4CompletedJanssen-Cilag International NV932021-07-222025-04-27
Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building
Risperidone, Aripiprazole, Ziprasidone - Schizophrenia
Phase 4UnknownShanghai Mental Health Center3502021-05-012020-08-26
Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone
PERSERIS, Risperidone - Schizophrenia
Phase 4CompletedIndivior Inc.692019-06-282021-07-07
A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities
Risperidone 3 mg, Paliperidone Palmitate 50 mg eq., Paliperidone Palmitate 75 mg eq. - Schizophrenia
Phase 4CompletedJanssen Research & Development, LLC342018-10-182025-04-27
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
Digital Medicine System, Aripiprazole, Olanzapine - Schizophrenia, Schizoaffective Disorder
Phase 4CompletedOtsuka Pharmaceutical Development & Commercialization, Inc.442018-05-212020-07-16
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia
Risperidone - Schizophrenia Spectrum and Other Psychotic Disorders
Phase 4CompletedWeill Medical College of Cornell University262017-09-152024-05-06
A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward Pathway
risperidone, aripiprazole, bupropion - Diagnosis and Treatment of Depression
Phase 4UnknownPeking University3002017-06-012017-05-12
Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia
Risperidone, Risperidone and Ramelteon, Haloperidol - Schizophrenia
Phase 4CompletedAll India Institute of Medical Sciences, Bhubaneswar1202017-05-012019-05-03
Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders
Methylphenidate, Risperidone - Attention Deficit/Hyperactivity Disorder, Oppositional Defiant Disorder
Phase 4TerminatedSheba Medical Center52017-02-012020-03-18
Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder
Clozapine, Risperidone, Olanzapine - Bipolar Disorder
Phase 4UnknownHospital de Clinicas de Porto Alegre542015-10-012018-10-02

Showing 20 of 147. Sign in to see all of them.

Conditions studied

Schizophrenia (98)  ·  Psychotic Disorders (42)  ·  Bipolar Disorder (13)  ·  Aggression (6)  ·  Dementia (6)  ·  Alzheimer Disease (5)  ·  Psychomotor Agitation (5)  ·  Attention Deficit Disorder with Hyperactivity (4)  ·  Autistic Disorder (3)  ·  Conduct Disorder (3)  ·  Diabetes Mellitus (3)  ·  Mental Disorders (3)  ·  Metabolic Syndrome (3)  ·  Oppositional Defiant Disorder (3)  ·  Recurrence (3)

Sponsors

Northwell Health (8)  ·  University of California, Los Angeles (6)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (5)  ·  Eli Lilly and Company (4)  ·  Janssen Korea, Ltd., Korea (4)  ·  Central South University (3)  ·  Fundación Marques de Valdecilla (3)  ·  Janssen Pharmaceutica N.V., Belgium (3)  ·  Janssen, LP (3)  ·  Massachusetts General Hospital (3)  ·  Otsuka Pharmaceutical Development & Commercialization, Inc. (3)  ·  All India Institute of Medical Sciences, Bhubaneswar (2)  ·  AstraZeneca (2)  ·  Creighton University (2)  ·  Dartmouth-Hitchcock Medical Center (2)

Countries

United States (70)  ·  China (12)  ·  Taiwan (8)  ·  Germany (7)  ·  South Korea (7)  ·  Canada (5)  ·  India (5)  ·  Israel (5)  ·  Greece (4)  ·  Norway (4)  ·  Spain (4)  ·  United Kingdom (4)  ·  Brazil (3)  ·  Czechia (3)  ·  Argentina (2)

Top investigators

Benedicto Crespo-Facorro, Professor (3)  ·  Delbert Robinson, MD (2)  ·  Frederick Petty, MD, PhD (2)  ·  Joseph Biederman, MD (2)  ·  Keith H. Nuechterlein, PhD (2)  ·  Knut Engedal, Ph D (2)  ·  Wei Hao, MD., Ph.D. (2)

Results publications

PMID 26107752, PMID 37811711, PMID 40779812, PMID 11559786, PMID 12509667, PMID 12823080, PMID 14661862, PMID 14735295, PMID 15000267, PMID 15056517, PMID 15289699, PMID 16172203, PMID 16185814, PMID 16452559, PMID 16585434, PMID 16585435, PMID 16801664, PMID 16831113, PMID 17015817, PMID 17054789, PMID 17151158, PMID 17151159, PMID 17287825, PMID 17321111, PMID 17335321, PMID 17502776, PMID 17667476, PMID 17667477, PMID 17898351, PMID 17917554, PMID 18052570, PMID 18590519, PMID 18794207, PMID 1883257, PMID 18840034, PMID 19228178, PMID 1950621, PMID 19640511, PMID 19814947, PMID 19890258, PMID 20216424, PMID 20231321, PMID 20334680, PMID 20441726, PMID 20457512, PMID 20494268, PMID 20664583, PMID 20688481, PMID 20812791, PMID 20816031

NIH funding

P50MH066286 (2), R01MH037705 (2), R01MH060004 (2), K23MH074540 (1), M01RR000069 (1), N01MH090001 (1), N01MH90001 (1), R01AG021488 (1), R01DA032533 (1), R01MH041573 (1), R01MH045074 (1), R01MH057292 (1), R01MH059312 (1), R01MH060845 (1), R01MH071536 (1)